

NOTICE OF ANNUAL GENERAL MEETING OF GENOVIS AB (PUBL)

The shareholders of Genovis AB (publ), reg.no. 556574-5345, with its registered office in Kävlinge kommun, Skåne län, are hereby summoned to the Annual General Meeting, to be held on Monday, 18 May 2026, at 17.00 p.m., at Genovis AB's office, Karl Johans väg 104, Kävlinge.

4:30 p.m. – 4:50 p.m. Registration 5:00 pm Annual General Meeting convened

Right to Participate and Registration

Shareholders who wish to participate in the General Meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday, 7 May 2026, and must have notified the Company of their intention to attend no later than Tuesday, 12 May 2026, preferably before 15:00. Registration may be submitted by post to Genovis AB c/o Advokatfirman Källén AB, Stora Tomtegatan 5, 223 51 Lund, or by e-mail: arne@advkallen.se When registering, please state your name/company name and personal identity number/corporate registration number, address and telephone number. The notification should also state the number of assistants (maximum two) the shareholder intends to bring to the meeting.

In order to be entitled to participate in the General Meeting, a shareholder whose shares are held in the name of a nominee must, in addition to notifying the Company of their intention to attend, have the shares registered in their own name so that the shareholder is included in the presentation of the share register as of the record date, Thursday, 7 May 2026. Such re-registration may be temporary (so-called voting rights registration) and must be requested from the nominee in accordance with the nominee's procedures and in such time in advance as the nominee determines. Voting rights registrations completed by the nominee no later than Tuesday, 12 May 2026 will be taken into account in the preparation of the share register.

Proxies

A shareholder who is represented by a proxy must issue a written, signed and dated power of attorney to the proxy. Such power of attorney should be submitted in connection with the registration. The validity of a power of attorney may not exceed five years from the date of issue. A proxy form is available on the Company's website, <https://investor.genovis.com/en/corporate-governance/general-meeting/>. A representative of a legal entity must present a copy of the certificate of registration or equivalent authorization documents demonstrating the authorized signatory.

Proposed Agenda

1. Opening of the meeting.
2. Election of chairperson of the meeting.

3. Preparation and approval of the voting list.
4. Approval of the agenda.
5. Election of persons to verify the minutes.
6. Examination of whether the meeting has been duly convened.
7. Address by the Chief Executive Officer.
8. Presentation of the annual report and consolidated accounts and the auditor's report.
9. Resolution on:
 - a) adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet,
 - b) allocation of the Company's profit or loss in accordance with the adopted balance sheet,
 - c) discharge from liability for the members of the Board of Directors and the Chief Executive Officer.
10. Resolution on the number of members of the Board of Directors and deputy members to be elected by the General Meeting.
11. Resolution on fees to the members of the Board of Directors.
12. Election of members of the Board of Directors and the Chairman of the Board.
13. Resolution on fees to the auditors.
14. Election of auditor.
15. Resolution regarding the nomination committee.
16. Resolution on guidelines for remuneration of senior executives.
17. Resolution of authorization for the Board of Directors to resolve on new share issues.
18. Resolution on authorization for the Board of Directors to resolve on repurchase and transfer of own shares, conditional upon the adoption of legislative proposal prop. 2025/26:125.
19. Resolution on authorization for the Chief Executive Officer to make such formal adjustments to the resolutions as may be required in connection with their registration and implementation.

20. Closing of the meeting.

Item 2 – Proposed Chairperson of the Meeting

The nomination committee proposes attorney Arne Källén as chairperson of the meeting.

Item 10 – Number of Members of the Board of Directors and Deputy Members

The nomination committee proposes that the Board of Directors shall consist of five ordinary members without deputies.

Item 11 – Fees to the Members of the Board of Directors

The nomination committee proposes that fees until the end of the next Annual General Meeting shall be paid in the amount of SEK 240,000 to each member of the Board of Directors who is not employed by the Company, and SEK 590,000 to the Chairman of the Board.

Item 12 – Election of Members of the Board of Directors and Chairman of the Board

The nomination committee proposes the re-election of Torben Jørgensen, Mikael Lönn, Steve Jordan, Magnus Gustafsson and Lotta Ljungqvist as members of the Board.

The nomination committee proposes the re-election of Torben Jørgensen as Chairman of the Board.

Item 13 – Fees to the Auditors

The nomination committee proposes that fees to the auditors shall be paid in accordance with approved invoices.

Item 14 – Election of Auditor

The nomination committee proposes the re-election of the registered audit firm Öhrlings PricewaterhouseCoopers AB ("PWC"). PWC has announced that, if elected, PWC will appoint Neda Feher as the auditor in charge.

Item 15 – Resolution Regarding the Nomination Committee

The nomination committee proposes that the nomination committee for the Annual General Meeting 2027 shall consist of representatives of the four largest shareholders as of the last banking day in August prior to the Annual General Meeting. The nomination committee shall appoint a chairperson from among its members. It shall be the responsibility of the Chairman of the Board to convene the nomination committee. If any owner declines to participate in the nomination committee, the right to appoint a representative shall pass to the next largest shareholder not already represented on the nomination committee. If, as a result of changes in ownership, it is deemed appropriate, the nomination committee may invite additional shareholders to take a seat on the nomination committee, provided that the total number of members does not exceed five. If a member of the nomination committee were to leave the committee before its work is complete, the nomination committee shall, if it deems this necessary, request the same shareholder, or, if that shareholder is no longer among the larger shareholders, the next largest shareholder in terms of size, to appoint a replacement. Any such change shall be announced on the Company's website. If only marginal changes in voting rights have occurred, or if the change occurs later than three months before the Annual General Meeting, no changes to the composition of the nomination committee shall be made, unless there are special reasons for doing so.

The nomination committee shall prepare proposals to be submitted to the Annual General Meeting for resolution regarding the chairperson of the meeting, the Chairman and other members of the Board of Directors, the auditor, fees to the Board of Directors and the auditor, and principles for the appointment of the nomination committee. The mandate of the nomination committee runs until a new nomination committee has been appointed.

The nomination committee proposes that remuneration shall only be paid for direct costs incurred in connection with the assignment.

Item 16 – Guidelines for Remuneration of Senior Executives

The Board of Directors proposes that the Annual General Meeting resolve on the following guidelines for remuneration of senior executives. Senior executives means the Chief Executive Officer and other members of group management. In the event that a member of the Board of Directors performs work for Genovis beyond board duties, consulting fees or other remuneration may be paid for such work. The guidelines shall apply to remuneration agreed upon, and changes made to previously agreed remuneration, after the guidelines have been adopted by the Annual General Meeting 2026. The guidelines do not cover remuneration resolved by the General Meeting.

Promotion of the Company's Business Strategy, Long-Term Interests and Sustainability

In brief, the Company's business strategy is to develop innovative and effective solutions for the research, development and manufacture of pharmaceuticals. The strategy for conducting successful operations and achieving the Company's financial goals consists of developing new innovative products, building long-term customer relationships and inorganic growth initiatives within the focus areas: biochemical analysis, diagnostics and applications in the manufacture of biological pharmaceuticals. Further information about the Company's business strategy is available at www.genovis.com.

Successful implementation of the Company's business strategy and safeguarding of the Company's long-term interests, including its sustainability, requires the Company to be able to recruit and retain qualified employees. This requires the Company to be able to offer competitive remuneration. These guidelines enable senior executives to be offered competitive total remuneration.

Variable cash remuneration covered by these guidelines shall aim to promote the Company's business strategy and long-term interests, including its sustainability.

Forms of Remuneration, etc.

Remuneration shall be market-based and may consist of the following components: fixed annual salary, variable cash remuneration, pension benefits, other benefits and severance pay. In addition, and independently of these guidelines, the General Meeting may resolve on, for example, share and share price-related remuneration.

Fulfilment of criteria for the payment of variable cash remuneration shall be measurable over a period of one year and may amount to at most a certain percentage, see below, of the fixed cash annual salary.

Chief Executive Officer

The Company's Chief Executive Officer shall receive fixed and variable cash remuneration. Pension benefits, including health insurance, shall be defined contribution. Variable cash remuneration shall not qualify for pension. The Company shall make pension provisions of a maximum of 35 percent of the fixed cash annual salary. In addition to the fixed cash annual salary, the Chief Executive Officer shall receive variable cash remuneration that may amount to a maximum of 50 percent of the fixed cash annual salary per year. The variable portion of the cash remuneration is based on the Company achieving certain predetermined and measurable criteria, which may be financial or non-financial, and may also consist of individually adapted quantitative or qualitative targets. The criteria shall be designed to promote the Company's business strategy and long-term interests, including its sustainability, by for example having a clear link to the business strategy or promoting the Chief Executive Officer's long-term development.

Other Senior Executives

This group shall receive a market-based fixed cash annual salary as well as variable cash remuneration that may amount to a maximum of 50 percent of the fixed annual salary per year. The variable cash remuneration shall be based on the Company achieving certain predetermined and measurable criteria, which may be financial or non-financial (such as ESG). The variable cash remuneration shall also, to a certain extent, be based on predetermined targets related to individual performance and shall consist of predetermined and measurable quantitative or qualitative targets. The criteria shall be designed to promote the Company's business strategy and long-term interests, including its sustainability, by for example having a clear link to the business strategy or promoting the executive's long-term development.

Pension benefits, including health insurance, shall be defined contribution unless the executive is covered by defined benefit pension under mandatory collective bargaining agreement provisions. Variable cash remuneration shall qualify for pension to the extent required by mandatory collective bargaining agreement provisions applicable to the executive. Pension premiums for defined contribution pension may amount to a maximum of 35 percent of the fixed annual salary.

Conditions for Variable Remuneration and Performance Requirements

Variable cash remuneration is linked to certain predetermined and measurable criteria as described above. When the measurement period for fulfilment of criteria for payment of variable cash remuneration has ended, an assessment shall be made of the extent to which the criteria have been met. The Board of Directors is responsible for the assessment regarding variable cash remuneration for the Chief Executive Officer. Regarding variable cash remuneration for other executives, the Chief Executive Officer is responsible for the assessment. Regarding financial targets, the assessment shall be based on the most recently published financial information of the Company.

Cash Remuneration in Extraordinary Circumstances

In addition to the above, additional variable cash remuneration may be paid in extraordinary circumstances, provided that such extraordinary arrangements are time-limited and only made at the individual level, either for the purpose of recruiting or retaining executives, or as remuneration

for extraordinary work efforts beyond the person's ordinary duties. Such remuneration may not exceed an amount corresponding to 35 percent of the fixed cash annual salary per year and may not be paid more than once per year and per individual. Any decisions on such remuneration shall be made by the Board of Directors.

Derogation from the Guidelines

The Board of Directors may resolve to temporarily derogate from these guidelines, in whole or in part, if the Board of Directors in an individual case assesses that there are special reasons warranting such derogation and it is necessary to serve the Company's long-term interests, including its sustainability, or to ensure the Company's financial viability.

Other Benefits

Senior executives may be granted customary benefits, which may include, inter alia, a company car, occupational health services and life insurance. Such benefits may amount to a maximum value corresponding to ten percent of the fixed cash annual salary.

Severance Pay

Upon termination by the Company, the notice period may be a maximum of 12 months. Fixed cash salary during the notice period and severance pay may together not exceed an amount corresponding to 18 months' fixed cash salary for the Chief Executive Officer and 12 months for other senior executives. Upon termination by the executive, the notice period may be a maximum of six months, without entitlement to severance pay.

In addition, remuneration for any non-compete undertaking may be paid. Such remuneration shall compensate for any loss of income and shall only be paid to the extent that the former executive does not have entitlement to severance pay. The remuneration shall be based on the fixed cash salary at the time of termination, unless otherwise required by mandatory collective bargaining agreement provisions, and shall be paid during the period in which the non-compete undertaking applies, which shall be a maximum of nine months after the end of employment.

Salary and Employment Conditions for Employees

In preparing the Board of Directors' proposal for these guidelines, salary and employment conditions for the Company's employees have been taken into account, with data on employees' total remuneration, the components of remuneration and the increase and rate of increase in remuneration over time having formed part of the Board of Directors' basis for decision in evaluating the reasonableness of the guidelines and the limitations that follow therefrom.

The Decision-Making Process for Determining, Reviewing and Implementing the Guidelines

The Board of Directors prepares proposals for guidelines for remuneration of senior executives. The Board of Directors shall prepare a proposal for new guidelines at least every four years and submit the proposal for resolution at the Annual General Meeting. The guidelines shall apply until new guidelines have been adopted by the General Meeting. The Board of Directors shall monitor and evaluate programs for variable remuneration for company management, the application of guidelines for remuneration of senior executives and current remuneration structures and levels in the Company. When the Board of Directors processes and resolves on remuneration-related matters, the Chief Executive Officer and other members of company management do not participate, to the extent they are affected by the matters.

Description of Material Changes to the Guidelines and How Shareholders' Views Have Been Taken into Account

Compared to the previously adopted guidelines, the following changes have been made to these proposed guidelines:

- An addition that the Chief Executive Officer's variable remuneration shall not qualify for pension.
- The maximum scope for other benefits has been made uniform across the group of senior executives. Previously, the maximum value was 15 percent of the cash annual salary for senior executives excluding the Chief Executive Officer, who had a limit of ten percent of the cash annual salary. The current proposal is a limit of ten percent of the cash annual salary for all senior executives.
- The percentage cap in the previous guidelines regarding any non-compete undertaking upon termination of employment has been removed, in order to compensate for the limitation following from such an undertaking.

Beyond what is mentioned above, no material changes have been made to these proposed guidelines compared to the previously adopted guidelines.

Item 17 – Board of Directors' Proposal for Authorization to Resolve on New Share Issues

The Board of Directors proposes that the General Meeting authorize the Board of Directors to resolve, on one or more occasions during the period up to and including the next Annual General Meeting, with or without preferential rights for shareholders, to issue new shares, convertibles or warrants. New issues may be made against cash payment and/or with provisions for payment in kind, set-off or other conditions. Through resolutions made pursuant to the authorization, the share capital may be increased by a total maximum of SEK 1,650,000 through the issuance of a total maximum of 6,600,000 new shares. In the event of issues without preferential rights for shareholders, the subscription price shall be market-based at the time of the issue resolution.

The reason for any deviation from shareholders' preferential rights shall be to broaden the shareholder base, raise or facilitate the raising of working capital, increase liquidity in the share, carry out company acquisitions or raise or facilitate the raising of capital for company acquisitions.

A valid resolution under this item requires that the resolution be supported by shareholders representing at least two thirds of both the votes cast and the shares represented at the General Meeting.

Item 18 – Authorization for the Board of Directors to Resolve on Repurchase and Transfer of Own Shares, Conditional upon the Adoption of Legislative Proposal prop. 2025/26:125

The Swedish Government has, in legislative bill 2025/26:125, proposed an amendment to the Swedish Companies Act (Sw. aktiebolagslagen) such that the possibility for public limited liability companies to acquire and transfer own shares shall also apply to companies whose shares are admitted to trading on an MTF platform, including Nasdaq First North Growth Market. The legislative amendments are proposed to enter into force on 5 December 2026. The Board of Directors' right to utilize the authorization is conditional upon the Swedish Companies Act being amended such that acquisition and transfer of own shares shall also be permitted for companies whose shares are admitted to trading on an MTF platform.

The Board of Directors proposes that the Annual General Meeting authorize the Board of

Directors to resolve, on one or more occasions during the period up to and including the next Annual General Meeting, to acquire and transfer own shares on the following terms.

Repurchases of shares may be made on Nasdaq First North Growth Market in accordance with the Nasdaq First North Growth Market Rulebook for Issuers of Shares. The maximum number of own shares that may be repurchased shall not exceed ten (10) percent of all shares in the Company at any given time. Repurchases of shares may only be made at a price per share within the prevailing price range for the share on Nasdaq First North Growth Market at the time of the repurchase. Repurchases shall be made against cash payment.

Transfers may be made of all own shares held by the Company at the time of the Board of Directors' transfer resolution. Transfers of own shares on Nasdaq First North Growth Market may only be made at a price per share within the prevailing price range for the share on Nasdaq First North Growth Market at the time of the transfer. Transfers of own shares in a manner other than on Nasdaq First North Growth Market shall be made against cash payment, through contribution of assets in kind or through set-off, and the price shall be determined such that the transfer is made on market-based terms. Transfers of own shares in a manner other than on Nasdaq First North Growth Market may be made with deviation from shareholders' preferential rights.

The purpose of an acquisition or transfer of own shares, and the reason for any transfer with deviation from shareholders' preferential rights, shall be to enable adjustment and improvement of the Company's capital structure in order to contribute to increased shareholder value, and to capitalize on strategic business opportunities by financing such opportunities in whole or in part with own shares.

The Board of Directors' proposal for a resolution to authorize the Board of Directors to resolve on repurchase and transfer of own shares is conditional upon the Swedish Companies Act being amended such that acquisition and transfer of own shares shall also be permitted for companies whose shares are admitted to trading on an MTF platform. The resolution shall not be valid and shall not be implemented in the event that the Swedish Parliament does not adopt such legislative amendments, or until such legislative amendments have entered into force.

Documents

The annual report, auditor's report, articles of association, proxy form and the other proposed resolutions will be available at the Company's offices at Karl Johans väg 104, Kävlinge and on the Company's website www.genovis.com no later than three weeks prior to the Annual General Meeting and will be sent to shareholders who so request and provide their postal address. The Nomination Committee's reasoned statement will be available at the above mentioned address no later than four weeks prior to the Annual General Meeting.

Number of Shares and Votes

At the time of issuance of this notice, the total number of shares and votes in the Company amounts to 66,062,792.

Information at the Annual General Meeting

Shareholders are reminded of their right to request information from the Board of Directors and the Chief Executive Officer at the General Meeting pursuant to Chapter 7, Sections 32 and 57 of the Swedish Companies Act. Shareholders that wish to submit written requests for such information in advance of the Annual General Meeting may do so to Genovis AB, Att: Legal, Box 4, 244 21 Kävlinge, or by e-mail to: legal@genovis.com.



Pressrelease April 15, 2026

Kävlinge, April 2026
Genovis AB (publ)
The Board of Directors

Contacts

Fredrik Olsson, CEO

Tel: +46 (0)70-276 46 56 fredrik.olsson@genovis.com

About Us

Headquartered in Kävlinge, Sweden, Genovis offers customers in the biopharmaceutical and research industries tools that facilitate and save time in the development of new treatment methods and diagnostics. Genovis' innovative products and technologies are used by scientists all over the world and the product formats streamline and improve workflows in biochemical analysis and sequencing, as well as in the development, quality control and manufacturing of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiaries Genovis Inc. (US) and SEQRNA AB. Genovis shares are listed on Nasdaq First North Growth Market and DNB Carnegie Investment Bank AB is the Company's Certified Adviser.

This is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.